UroGen Pharma Reports Q4 and Full Year 2025 Financial Results and ZUSDURI™ Launch Update
UroGen Pharma Ltd. Announces Q4 and Full Year 2025 Results; ZUSDURI™ Launch on Track
PRINCETON, NJ, March 2, 2026 — UroGen Pharma Ltd. (NASDAQ: URGN), a biotechnology company focused on developing and commercializing treatments for urothelial and specialty cancers, has released its financial results for the fourth quarter and full year ended December 31, 2025. The company also provided significant updates on its business operations, including the progress of its highly anticipated ZUSDURI™ launch.
Key Highlights
- ZUSDURI™ Launch On-Track: The company confirmed that the commercial launch of ZUSDURI™ is progressing as planned.
- Financial Results: UroGen reported a considerable increase in revenue for both the quarter and the full year, while also noting continued investments in research and development and commercialization efforts.
- Balance Sheet Position: The company highlighted its cash position and detailed its financing activities, including a refinancing of its existing term loan with Pharmakon Advisors, which provides additional non-dilutive capital at more favorable terms.
- Conference Call: UroGen’s management will host a conference call and webcast to discuss the results and provide a business update.
Financial Results in Detail
| Financial Metric |
Q4 2025 |
Q4 2024 |
FY 2025 |
FY 2024 |
| Revenue |
\$37,837,000 |
\$24,565,000 |
\$109,788,000 |
\$81,879,000 |
| Gross Profit |
\$34,548,000 |
Not disclosed |
Not disclosed |
Not disclosed |
| Research & Development Expenses |
\$14,314,000 |
\$14,894,000 |
\$67,107,000 |
\$57,145,000 |
| Selling, General & Administrative Expenses |
\$39,349,000 |
\$34,858,000 |
Not disclosed |
Not disclosed |
| Operating Loss |
\$(19,115,000) |
\$(27,658,000) |
\$(124,863,000) |
\$(96,782,000) |
| Net Loss |
\$(26,364,000) |
\$(37,512,000) |
\$(153,494,000) |
\$(126,874,000) |
| Total Assets |
\$200,455,000 |
\$285,711,000 |
|
| Total Liabilities |
\$305,929,000 |
\$294,514,000 |
|
| Total Shareholders’ Deficit |
\$(105,474,000) |
\$(8,803,000) |
|
What Investors Should Know
- Revenue Growth: UroGen’s revenues for the quarter and full year have shown significant year-over-year increases. This is a positive signal that the company’s commercial activities are gaining traction.
- Rising Expenses and Net Loss: The company continues to invest heavily in research and development and the commercialization of its pipeline, leading to a substantial net loss. Although this is common in the biotech sector, the magnitude of losses and growing shareholders’ deficit may be a concern for investors, especially if revenue does not accelerate further as product launches ramp up.
- Shareholders’ Deficit: Total shareholders’ deficit has widened dramatically to over \$105 million, compared to a deficit of about \$8.8 million a year earlier. This reflects the cumulative losses and is a metric investors should monitor closely, as it could affect future capital raising and share dilution risk.
- ZUSDURI™ Launch: The company’s confirmation that its ZUSDURI™ launch is on schedule is potentially price-sensitive. The commercial success of this product is likely critical for UroGen’s future revenue growth and valuation.
- Refinancing Activity: UroGen refinanced its term loan with Pharmakon Advisors, improving terms and adding non-dilutive capital. This move could reduce financing risk and provide needed runway, which should be viewed positively by shareholders.
- Conference Call for Investors: Management will discuss these results in detail on a webcast, providing an opportunity for investors to ask questions and get updated guidance.
Potential Share Price Movers
- Execution of ZUSDURI™ Launch: Successful commercialization could materially affect revenue trajectory and investor sentiment.
- Balance Sheet Health: The growing deficit and ongoing losses highlight the need for careful monitoring of cash burn and potential dilution risks. Any updates on further financing or improved cash flow during the conference call could impact the share price.
- Regulatory or Commercial Milestones: As with all biotech companies, any news regarding regulatory approvals, new clinical data, or competitive positioning for ZUSDURI™ and other pipeline assets will be highly price sensitive.
Contact Information
Investor Contact: Vincent Perrone, Senior Director, Investor Relations
Email: [email protected]
Phone: 609-460-3588 ext. 1093
Media Contact: Cindy Romano, Director, Corporate Communications
Email: [email protected]
Phone: 609-460-3566 ext. 1083
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to read UroGen Pharma’s full annual report and consult their financial advisor before making investment decisions. The information presented here is based on UroGen’s SEC filings and press releases dated March 2, 2026, and may contain forward-looking statements subject to risks and uncertainties.
View UroGen Pharma Ltd. Historical chart here
